

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>In re United States Patent Application of:</b>	)	<b>Docket No.:</b>	<b>4354-110</b>
	)		
<b>Applicants:</b>	)	<b>Conf. No.:</b>	<b>4322</b>
<b>Application No.:</b>	)	<b>Art Unit:</b>	<b>1614</b>
<b>Date Filed:</b>	)	<b>Examiner:</b>	<b>Phyllis G. Spivack</b>
<b>Title:</b>	)	<b>Customer No.:</b>	<b>23448</b>
	)		
<b>RIFALAZIL COMPOSITIONS AND THERAPEUTIC REGIMENS</b>	)		

**CERTIFICATE OF EFS FILING**

I hereby certify that this document is being filed via EFS in the United States Patent and  
Trademark Office on **January 5, 2010**.  
*/david bradin/*

**RESPONSE TO DECEMBER 31, 2009 INTERVIEW SUMMARY IN  
U.S. PATENT APPLICATION NO. 10/668,792**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

On December 31, 2009, Examiner Phyllis G. Spivack issued an Interview Summary setting out the particulars of a December 29, 2009 teleconference regarding matters in the above-identified U.S. patent application.

The undersigned attorney confirms the acceptability of the Interview Summary as provided by the Examiner, and notes that in accordance with the Examiner's statements, a Request for Examination (RCE) was filed in the present application on December 31, 2009.

Respectfully submitted,

*/david bradin/*  
David Bradin  
Reg. No. 37,783  
Attorney for Applicant(s)

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
Phone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney File No.: 4354-110

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284